Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a new partnership with HealingMaps, the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (“TMS”) clinics, and Advanced Behavioral Strategies (ABS).

The collaboration comes on the heels of HealingMaps and Capstone Management Group announcing their official launch of the Healing Health Alliance*, the first-of-its-kind Group Purchasing Organization (“GPO”) dedicated to supporting ketamine clinics, psilocybin retreats, TMS clinics, and more. It will provide HealingMaps’ large and growing provider network with one-stop purchasing and preferred pricing for Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain health analytics platform.

Addressing a Critical Gap in Care

Today, most neurological and mental health clinics rely on patient-reported questionnaires or subjective assessments to guide treatment and measure success. Firefly’s platform replaces this with a simple, non-invasive EEG assessment that uses AI to analyze brain activity across multiple regions, comparing patient data against Firefly’s proprietary database - the world’s largest known normative EEG/ERP data repository.

Key Benefits for Clinics

• Objective, FDA-Cleared Analytics: Standardized brain health insights that complement ketamine, psilocybin, and TMS treatment models.
• Demonstrated Outcomes: Providers can show patients measurable brain health changes correlated to treatment.
• Improved Patient Confidence: Objective data builds trust, enhances transparency, and supports long-term care engagement.
  

“Firefly’s mission is to harness the power of AI and EEG to transform brain health,” said Greg Lipschitz, Chief Executive Officer of Firefly Neuroscience. “By partnering with HealingMaps, we are significantly expanding access to our FDA-cleared brain analytics platform, empowering ketamine, psilocybin, and TMS clinics to strengthen care, prove outcomes, and grow sustainable new revenue streams.”

Cory Jones, Co-Founder of HealingMaps, added, “HealingMaps exists to connect patients with trusted, innovative providers. Partnering with Firefly means our provider network can now access unique, objective brain health analytics that provide evidence-based outcome analyses and potential new revenue opportunities, while giving patients greater confidence in their care.”

About Firefly Neuroscience

Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 180,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.

Please visit www.fireflyneuro.com for more information.

About HealingMaps

HealingMaps is the leading global directory for finding trusted clinics and practitioners offering psychedelic-assisted therapy, ketamine treatments, TMS, and mental wellness solutions. By connecting individuals with qualified providers, HealingMaps helps make innovative therapies more accessible while empowering clinics with tools, partnerships, and resources to thrive.

* Sign up for the Healing Health Alliance GPO here. There is no obligation or cost to be a member.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Investor & Media Contact

Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.